



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Thanh G. Phan
✉ thanh.phan@monash.edu
Christopher G. Sobey
✉ c.sobey@latrobe.edu.au

RECEIVED 10 June 2023

ACCEPTED 21 July 2023

PUBLISHED 31 July 2023

CITATION

Phan TG, Lim R, Krause M, Chan ST, McDonald H, Gan P-Y, Zhang SR, Barreto Arce LJ, Vuong J, Thirugnanachandran T, Clissold B, Ly J, Singhal S, Hervet MV, Kim HA, Drummond GR, Wallace EM, Ma H and Sobey CG (2023) Corrigendum: Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT). *Front. Neurosci.* 17:1237920. doi: 10.3389/fnins.2023.1237920

COPYRIGHT

© 2023 Phan, Lim, Krause, Chan, McDonald, Gan, Zhang, Barreto Arce, Vuong, Thirugnanachandran, Clissold, Ly, Singhal, Hervet, Kim, Drummond, Wallace, Ma and Sobey. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)

Thanh G. Phan^{1,2*}, Rebecca Lim^{3,4}, Mirja Krause^{3,4}, Siow T. Chan^{3,4}, Hannah McDonald^{3,4}, Poh-Yi Gan^{5,6}, Shengpeng R. Zhang⁷, Liz J. Barreto Arce⁷, Jason Vuong^{1,2}, Tharani Thirugnanachandran^{1,2}, Benjamin Clissold^{1,2}, John Ly^{1,2}, Shaloo Singhal^{1,2}, Marie Veronic Hervet^{1,2}, Hyun Ah Kim⁷, Grant R. Drummond⁷, Euan M. Wallace^{4,8}, Henry Ma^{1,2} and Christopher G. Sobey^{7*}

¹Clinical Trials, Imaging and Informatics Division, Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia, ²Department of Neurology, Monash Health, Clayton, VIC, Australia, ³The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia, ⁴Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia, ⁵Department of Medicine, Centre for Inflammatory Diseases, Monash Medical Centre, School of Clinical Sciences, Monash University, Clayton, VIC, Australia, ⁶Department of Immunology, Monash Health, Monash Medical Centre, Clayton, VIC, Australia, ⁷Department of Microbiology, Anatomy, Physiology and Pharmacology, Centre for Cardiovascular Biology and Disease Research, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, VIC, Australia, ⁸Victorian Department of Health, Melbourne, VIC, Australia

KEYWORDS

stem cell, clinical trial, ischemic stroke, phase I, allogeneic

A corrigendum on

Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)

by Phan, T. G., Lim, R., Krause, M., Chan, S. T., McDonald, H., Gan, P.-Y., Zhang, S. R., Barreto Arce, L. J., Vuong, J., Thirugnanachandran, T., Clissold, B., Ly, J., Singhal, S., Hervet, M. V., Kim, H. A., Drummond, G. R., Wallace, E. M., Ma, H., and Sobey, C. G. (2023). *Front. Neurosci.* 17:1153231. doi: 10.3389/fnins.2023.1153231

In the published article, there was an error in the author list, and author “Mirja Krause” was erroneously excluded. The corrected author list and author contributions section are appears below.

“Thanh G. Phan^{1,2*}, Rebecca Lim^{3,4}, Mirja Krause^{3,4}, Siow T. Chan^{3,4}, Hannah McDonald^{3,4}, Poh-Yi Gan^{5,6}, Shengpeng R. Zhang⁷, Liz J. Barreto Arce⁷, Jason Vuong^{1,2}, Tharani Thirugnanachandran^{1,2}, Benjamin Clissold^{1,2}, John Ly^{1,2}, Shaloo Singhal^{1,2},

Marie Veronic Hervet^{1,2}, Hyun Ah Kim⁷, Grant R. Drummond⁷, Euan M. Wallace^{4,8}, Henry Ma^{1,2} and Christopher G. Sobey^{7*}»

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Author contributions

TP, HMa, RL, EW, and CS designed the trial protocol and were major contributors in the writing of the manuscript. JV performed image analysis. TT, BC, JL, and SS recruited patients and performed clinical assessments. RL, MK, SC, and HMc prepared cells for administration to patients. MH administered cell infusions and collected the patient data. P-YG, SZ, LB, and HK performed the analyses of blood samples for inflammatory markers. CS and GD analyzed the data. All authors contributed to the article and approved the submitted version.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.